Mirae Asset Global Investments Co. Ltd. Buys 6,572 Shares of IDEXX Laboratories, Inc. $IDXX

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,781 shares of the company’s stock after purchasing an additional 6,572 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in IDEXX Laboratories were worth $29,619,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after buying an additional 86,040 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after acquiring an additional 605,290 shares in the last quarter. Invesco Ltd. boosted its holdings in IDEXX Laboratories by 14.0% in the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after acquiring an additional 161,782 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after acquiring an additional 187,967 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after acquiring an additional 326,348 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last ninety days. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Up 3.4%

Shares of IDXX stock opened at $589.25 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market capitalization of $46.80 billion, a price-to-earnings ratio of 45.08, a PEG ratio of 3.46 and a beta of 1.72. IDEXX Laboratories, Inc. has a 52-week low of $402.85 and a 52-week high of $769.98. The company has a 50-day simple moving average of $601.30 and a two-hundred day simple moving average of $654.85.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IDXX shares. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday. They set a “neutral” rating and a $650.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $760.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.